瑞舒伐他汀治疗不稳定型心绞痛的临床效果及对血脂、hs-CRP、Hcy、cTnl水平的影响

Clinical effect of rosuvastatin on unstable angina and the influence on serum lipids, hs-CRP, Hey and cTnl

目的 探讨瑞舒伐他汀治疗不稳定型心绞痛的临床效果及其对血脂、超敏C反应蛋白（hs-CRP）、同型半胱氨酸（Hcy）、肌钙蛋白（c Tnl）水平的影响。方法 选择2014年3月~2016年3月本院收治的200例不稳定型心绞痛（UAP）患者为实验研究对象,将其随机分为对照组和实验组各100例。对照组实施常规治疗方案,实验组在常规治疗基础上增用瑞舒伐他汀治疗,观察并比较2组患者临床疗效,检测治疗前后2组患者血脂、超敏C反应蛋白（hs-CRP）、同型半胱氨酸（Hcy）、肌钙蛋白（c Tnl）水平。结果实验组与对照组治疗总有效率分别为92%、80%,比较差异具有统计学意义（P〈0.05）。治疗前,2组患者血脂、hs-CRP、Hcy及c Tnl等水平差异均无统计学意义;治疗后,2组患者血脂、hs-CRP、Hcy及c Tnl水平均出现明显下降,高密度脂蛋白胆固醇（HDL-C）水平较治疗前明显升高,且实验组下降或升高幅度较对照组明显,差异具有统计学意义（P〈0.05）。结论 瑞舒伐他汀在治疗UAP的临床治疗中具有显著疗效,不但能够显著降低患者血脂,而且能减少患者炎症反应,对不稳定型心绞痛患者临床治疗具有一定帮助作用,值得临床推广应用。

Objective To explore the clinical effect of rosuvastatin in treatment of unstable angina and the influence of levels on blood lipids, hypersensitive C-reactive protein （hs-CRP） , homocysteine （Hey） and cardiac troponin （cTnl）. Methods 2 0 0 patients w i t h u n s t a b l e a n g i n a pectoris （UAP） in our hospital from March 2014 to March 2016 were selected as the subjects of the study, they were randomly divided into control group and experimental group, each group had 100 cases. The control group was given conventional treatment, the experimental group was given rosuvastatin on the basis of conventional treatment, the clinical efficacy between two groups was observed and compared, and the levels of blood lipid and C reactive protein （hs-CRP） , homocysteine （Hey） troponin I （cTnl） pre-and post-treatment were detected. Results T h e total effective rate of t h e e x p e r i m e n t a l g r o u p w a s 92% and the control group was 80% , the difference was statistically significant （P 〈0. 05）. Before treatment, the blood lipid, hs-CRP, Hey and cTnl between two groups showed no significant difference; after t r e a t m e n t , t h e b l o o d lipid, hs-CRP, Hey and c T n l in b o t h t w o g r o u p s were d e c r e a s e d , h i g h density lipoprotein cholesterol （HDL-C） levels than before treatment significantly increased, and the experimental group decreased or increased significantly compared with the control group, the difference was statistically significant （P 〈0. 05）. Conclusion R o s u v a s t a t i n h a s r e m a r k a b l e curative effect in clinical treatment for UAP, not only can significantly reduce the blood lipid, and reduce inflammation in patients, the clinical treatment of unstable angina patients have help, it is worthy of clinical application.